進入內容區塊

國立陽明交通大學資訊管理研究所

::: 網站導覽 回首頁 EN 陽明交大首頁
  • 字型大小-小
  • 字型大小-中
  • 字型大小-大

郎慧珠

exchangealt EN
  • 發布日期：115-05-18
  • 更新日期：115-05-21
  • 發布單位：資訊管理研究所
 
郎慧珠照片

教授
郎慧珠

研究室　　　護理館5樓521室
聯絡電話　　(02)2826-7015
傳真電話　　(02)2823-7298
電子信箱　　hclang@nycu.edu.tw
 
 
研究領域
成本效益評估
醫院績效管理
 
開授課程
健康科技與經濟評估
醫院作業管理
醫療決策分析
 
 
 
  • 學歷
    • 美國約翰霍普金斯大學醫療管理博士
    • 國立陽明大學公共衛生碩士
    • 中國醫藥大學公共衛生學士
  • 經歷
    • 國立陽明大學醫務管理研究所 副教授
    • 國立陽明大學醫務管理研究所 助理教授
    • 國立陽明大學醫務管理研究所 講師
  1. Lin WY1, Tan EC 2, Cheng E, Lang HC*. Real-World Cost-Effectiveness of Post-Acute Care or General Rehabilitation Care. MOST 105-2410-H-010 -012 -SS2.
  2. Tzeng YH, Yin WH, Lin KC, Wei J, Liou HR, Sung HJ, Lang HC. Factors Associated With the Utilization of Outpatient Virtual Clinics: Retrospective Observational Study Using Multilevel Analysis. J Med Internet Res. 2022 Jul 31. doi: 10.2196/40288. Epub ahead of print. PMID: 35917486.
  3. Chiu CM, Lin CS, Chen MS, Lang HC*. Evaluating the Comparative Efficiency of Medical Centers in Taiwan: A Dynamic Data Envelopment Analysis Application. BMC Health Services Research. 2022; Apr 2;22(1):435. 台灣19家醫學中心之財務結構與營運效能分析 PI-亞東醫院產學合作
  4. Chiou LJ, Lang HC*. Potentially Preventable Hospital Readmissions after Patients’ First Stroke in Taiwan. Submitted to Scientific Report. MOST 105-2410-H-010 -012 -SS2. Science Report 2022; Mar 8;12(1);3743. doi: 10.1038/s41598-022-07791-3.
  5. Leung JH, Chang CW, Chan AL, Lang HC*. Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan. Future Oncol. 2022 Feb 2. doi: 10.2217/fon-2021-0785. Online ahead of print. 醫藥品查驗中心
  6. Lin CS, Chiu CM, Huang YC, Lang HC*, Chen MS*. Evaluating the Operational Efficiency and Quality of Tertiary Hospitals in Taiwan: The Application of the EBITDA Indicator to the DEA Method and TOBIT Regression. Healthcare (Basel). 2021 Dec 29;10(1):58. doi: 10.3390/healthcare10010058. 台灣19家醫學中心之財務結構與營運效能分析 PI-亞東醫院產學合作
  7. 郎慧珠. COVID-19疫情對於醫療產業及民眾健康之衝擊及反思. 人文與社會科學簡訊. 科技部人文及社會科學研究發展司.2021; 22(4): 31-37.
  8. Leung JH, Lang HC, Wang SY, Lo HF, Chan AL. Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer. Expert Rev Pharmacoecon Outcomes Res. 2022 Apr; 22(3): 489-496. doi: 10.1080/14737167.2021.1954506. 全民健康保險納入癌症新藥之衝擊 PI MOST 107-2410-H-010-011
  9. Leung WC, Lang HC, Wang SY, Leung H, Chan LF. Cost‐utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck. Expert Review of Pharmacoeconomics & Outcomes Research. 2021Jun;21(3):489-495. doi: 10.1080/14737167.2021.1890585. Epub 2021 Mar 17. 全民健康保險納入癌症新藥之衝擊 PI MOST 107-2410-H-010-011
  10. Yang CP, Li CY, Huang WJ, Yu HL, Yang CC, Lu MC, Lang HC*, Yan YH*. Short-, mid- and long-term associations between PM2.5 and stroke incidence in Taiwan. J Occup Environ Med 2021 Sep 1;63(9):742-751.採用健保資料庫進行風險校正之成本效益分析:以腦中風治療為例 MOST 105-2410-H-010 -012 -SS2
  1. Chiu CM, Huang Y, Chen MS, Lin CS, Lang HC*. The Efficiency Analysis of 19 Medical Centers in Taiwan, was accepted to ISPOR Asia Pacific 2020. ISPOR Asia Pacific 2020. Virtual conference
  2. Lang HC, Tan ECH, Lin WY, Chang CW. Real-World Cost and Effectiveness Analysis Of Post-Acute Care Vs. Non-Pac for Stroke Patients after Discharge from Hospital. ISPOR 2019 Europe 2-6 November 2019, Copenhagen, Denmark.
  3. Chang CW (張智雯). Cost-effectiveness of the Second Line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC). ISPOR 2019. 18-22 May 2019. New Orleans, LA, USA.
  4. Kuo WJ(郭琬蓉), Lang HC, Lin CL. Budget Impact Analysis of Novel Direct-Acting Antivirals for Chronic Hepatitis C Virus Infection in Taiwan. ISPOR 2019. 18-22 May 2019. New Orleans, LA, USA.
  5. Lang HC, Tan ECH, Yang CK, Chang CW, Yang MH. Cost-effectiveness of immunotherapy strategies for advanced melanoma in Taiwan. ISPOR Asia Pacific 2018. 8-11 September 2018, Tokyo, Japan.
  6. Lang HC, Lin WC, Niu DM. Economic Evaluation of Neonatal Screening for Congenital Hypothyroidism. ISPOR 20th Annual European Congress4-8 November 2017, Glasgow, Scotland
  7. Lin YL, Lang HC*. Cost-Effectiveness Analysis of Laparoscopic Surgery for Presumed Leiomyomas.ISPOR 19th Annual European Congress. 29 Oct.-2 Nov. 2016, Vienna, Austria
  8. Chen RCY, Lang HC, Chuang SY, Cheng HM. Application Of Risk Adjusted Cost-Effectiveness Analyses For Stroke Treatment. ISPOR 19th Annual European Congress. 29 Oct.-2 Nov. 2016, Vienna, Austria
  9. Lang HC, Cheng E. The Relationship between Economic Business Cycle and Health Care Utilization. iHEA Italy, Milan July 13-15, 2015
  10. Wang YP, Lang HC, Lu CL. Use of ursodeoxycholic acid and the risk of colorectal cancer: a nationwide, population based, case-control database study
回上一頁
gotop